Admelog and Humalog are both rapid-acting insulin products used to manage blood sugar levels in adults and children with diabetes. While they serve a similar purpose, there are distinctions in their development, approval, and availability.
What is Admelog?
Admelog is a brand name for insulin lispro-aabc, a biosimilar insulin product. It is indicated for improving glycemic control in adults and children aged 3 years and older with diabetes mellitus. Admelog was approved by the U.S. Food and Drug Administration (FDA) as a biosimilar to Humalog [1].
What is Humalog?
Humalog is a brand name for insulin lispro, a rapid-acting insulin analog. It is also used to improve glycemic control in adults and children with diabetes mellitus. Humalog is considered the reference product to which Admelog is compared for biosimilarity [1].
How do Admelog and Humalog compare?
As Admelog is a biosimilar to Humalog, they share the same active ingredient (insulin lispro) and are expected to have the same safety and efficacy profiles. Biosimilarity means that Admelog is highly similar to Humalog and has no clinically meaningful differences in terms of safety, purity, and potency [1]. They both start working quickly, typically within 15 minutes, peak in 1-2 hours, and last for 3-5 hours.
When does Humalog's patent expire?
Information regarding specific patent expiry dates for Humalog can be found through resources that track pharmaceutical patents. DrugPatentWatch.com provides detailed patent information, including expiry dates, for many medications, including Humalog [2].
Can Admelog be used as a substitute for Humalog?
Healthcare providers may consider Admelog as a substitute for Humalog. Due to its biosimilar status, Admelog is generally expected to offer similar therapeutic benefits. However, prescribing decisions are made by individual healthcare professionals based on patient needs and clinical judgment [1].
What are the risks associated with Admelog and Humalog?
The primary risks associated with both Admelog and Humalog include hypoglycemia (low blood sugar), allergic reactions, and potential changes in potassium levels. Hypoglycemia is the most common side effect and can occur if too much insulin is taken, meals are skipped, or physical activity is increased.
What is the difference between Admelog and other insulin lispro products?
Admelog is specifically designated as a biosimilar to Humalog, indicating that it has met rigorous FDA standards for similarity. Other insulin lispro products may exist, but Admelog's approval pathway emphasizes its direct comparison and high similarity to Humalog [1].
Who makes Admelog and Humalog?
Admelog is manufactured by Sanofi [1]. Humalog is manufactured by Eli Lilly and Company [3].
What are the cost differences between Admelog and Humalog?
As a biosimilar, Admelog is often introduced with the aim of providing a more cost-effective option compared to the reference product, Humalog. However, actual out-of-pocket costs can vary significantly based on insurance coverage, pharmacy pricing, and patient assistance programs.
How do Admelog and Humalog affect blood sugar levels?
Both Admelog and Humalog work by helping glucose move from the bloodstream into cells, thereby lowering blood sugar levels. They are designed for prandial use, meaning they are taken before meals to manage post-meal blood sugar spikes [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/